JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $20
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $19 to $20.
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…
Gartner, Sony, Uber And Other Big Gainers From Tuesday
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has announced a global license agreement with Roche Holdings AG (OTC:RHHBY) and Genentech to develop and commercialize vixarelimab, a fully human…
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) and Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd., a subsidiary of Huadong Medicine Co., Ltd., have announced a strategic collaboration to develop and commercialize Kiniksa's Arcalyst and mavrilimumab in the Asia Pacific Region.
Kiniksa Pharmaceuticals: Q4 Earnings Insights
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q4 earnings results on Tuesday, February 22, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.